SMYD3 and hepatocellular carcinoma: In vitro interaction of SMYD3 with HBV has been demonstrated, showing that SMYD3 expression was upregulated by hepatitis B x protein (HBx) in HepG2 cells, promoting HCC development and clinical progression17.